Literature DB >> 20233393

Hormone replacement therapy advertising: sense and nonsense on the web pages of the best-selling pharmaceuticals in Spain.

Elisa Chilet-Rosell1, Marta Martín Llaguno, María Teresa Ruiz Cantero, Pablo Alonso-Coello.   

Abstract

BACKGROUND: The balance of the benefits and risks of long term use of hormone replacement therapy (HRT) have been a matter of debate for decades. In Europe, HRT requires medical prescription and its advertising is only permitted when aimed at health professionals (direct to consumer advertising is allowed in some non European countries). The objective of this study is to analyse the appropriateness and quality of Internet advertising about HRT in Spain.
METHODS: A search was carried out on the Internet (January 2009) using the eight best-selling HRT drugs in Spain. The brand name of each drug was entered into Google's search engine. The web sites appearing on the first page of results and the corresponding companies were analysed using the European Code of Good Practice as the reference point.
RESULTS: Five corporate web pages: none of them included bibliographic references or measures to ensure that the advertising was only accessible by health professionals. Regarding non-corporate web pages (n = 27): 41% did not include the company name or address, 44% made no distinction between patient and health professional information, 7% contained bibliographic references, 26% provided unspecific information for the use of HRT for osteoporosis and 19% included menstrual cycle regulation or boosting feminity as an indication. Two online pharmacies sold HRT drugs which could be bought online in Spain, did not include the name or contact details of the registered company, nor did they stipulate the need for a medical prescription or differentiate between patient and health professional information.
CONCLUSIONS: Even though pharmaceutical companies have committed themselves to compliance with codes of good practice, deficiencies were observed regarding the identification, information and promotion of HRT medications on their web pages. Unaffected by legislation, non-corporate web pages are an ideal place for indirect HRT advertising, but they often contain misleading information. HRT can be bought online from Spain, without a medical consultation or prescription constituting a serious issue for public health. In our information society, it is the right and obligation of public health bodies to ensure that such information is not misleading.

Entities:  

Mesh:

Year:  2010        PMID: 20233393      PMCID: PMC2850342          DOI: 10.1186/1471-2458-10-134

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  10 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  [Pharmaceutic promotion and publicity: quo vadis?].

Authors:  P Castillo Pérez
Journal:  Med Clin (Barc)       Date:  1992-09-19       Impact factor: 1.725

Review 3.  Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives.

Authors:  Nancy Krieger; Ilana Löwy; Robert Aronowitz; Judyann Bigby; Kay Dickersin; Elizabeth Garner; Jean-Paul Gaudillière; Carolina Hinestrosa; Ruth Hubbard; Paula A Johnson; Stacey A Missmer; Judy Norsigian; Cynthia Pearson; Charles E Rosenberg; Lynn Rosenberg; Barbara G Rosenkrantz; Barbara Seaman; Carlos Sonnenschein; Ana M Soto; Joe Thornton; George Weisz
Journal:  J Epidemiol Community Health       Date:  2005-09       Impact factor: 3.710

4.  Canadian clinicians and patients need clean, clear knowledge.

Authors:  J A Muir Gray
Journal:  CMAJ       Date:  2006-07-18       Impact factor: 8.262

5.  Drugs for pre-osteoporosis: prevention or disease mongering?

Authors:  Pablo Alonso-Coello; Alberto López García-Franco; Gordon Guyatt; Ray Moynihan
Journal:  BMJ       Date:  2008-01-19

6.  HRT in the early menopause: scientific evidence and common perceptions.

Authors:  A Pines; D W Sturdee; M H Birkhauser; T de Villiers; F Naftolin; A Gompel; R Farmer; D Barlow; D Tan; P Maki; R Lobo; H Hodis
Journal:  Climacteric       Date:  2008-08       Impact factor: 3.005

Review 7.  Exercise and estrogen or estrogen alternatives (phytoestrogens, bisphosphonates)for preservation of bone mineral in postmenopausal women.

Authors:  Philip D Chilibeck
Journal:  Can J Appl Physiol       Date:  2004-02

8.  Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics.

Authors:  D Grady; W Applegate; T Bush; C Furberg; B Riggs; S B Hulley
Journal:  Control Clin Trials       Date:  1998-08

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Disease mongering in drug promotion: do governments have a regulatory role?

Authors:  Barbara Mintzes
Journal:  PLoS Med       Date:  2006-04-11       Impact factor: 11.069

  10 in total
  4 in total

1.  Consumers Turning to the Internet Pharmacy Market: Cross-Sectional Study on the Frequency and Attitudes of Hungarian Patients Purchasing Medications Online.

Authors:  András Fittler; Róbert György Vida; Mátyás Káplár; Lajos Botz
Journal:  J Med Internet Res       Date:  2018-08-22       Impact factor: 5.428

2.  Online medication purchasing during the Covid-19 pandemic: potential risks to patient safety and the urgent need to develop more rigorous controls for purchasing online medications, a pilot study from the United Arab Emirates.

Authors:  Ammar Abdulrahman Jairoun; Sabaa Saleh Al-Hemyari; Naseem Mohammed Abdulla; Faris El-Dahiyat; Maimona Jairoun; Saleh Karamah Al-Tamimi; Zaheer-Ud-Din Babar
Journal:  J Pharm Policy Pract       Date:  2021-04-30

Review 3.  Gender bias in clinical research, pharmaceutical marketing, and the prescription of drugs.

Authors:  Elisa Chilet-Rosell
Journal:  Glob Health Action       Date:  2014-12-09       Impact factor: 2.640

4.  A Content Analysis of Testosterone Websites: Sex, Muscle, and Male Age-Related Thematic Differences.

Authors:  Nicholas Ivanov; Jimmy Vuong; Peter B Gray
Journal:  Am J Mens Health       Date:  2017-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.